Company / Cash & Equivalents
Ensign Group Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$503.9M
FY2025
5-year range
$262.2M / $509.6M
FY2021-FY2025
Trend
+8.5%
vs FY2024
Sector context
#47 of 148
Health Care
What the data says
At $504M, Ensign Group's cash & equivalents ranks #47 of 148 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $31M in FY2018 to $510M in FY2023.
Based on SEC 10-K filings.
$504M in FY2025 with a 5-year CAGR of +16.3%.
Remained stable around $504M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +16.8%
- 5-Year CAGR
- +16.3%
- 10-Year CAGR
- -
Sector benchmark
#47 of 148 in Health CareTop 32% of 148This company $503.9M Sector average $1.2B
▼
-57.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +16.3%, indicating consistent growth.
- In FY2025, cash & equivalents increased 8.5% year-over-year.
- Ranks #47 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $503.9M | +8.5% |
| FY2024 | $464.6M | -8.8% |
| FY2023 | $509.6M | +61.1% |
| FY2022 | $316.3M | +20.6% |
| FY2021 | $262.2M | +10.8% |
| FY2020 | $236.6M | +299.8% |
| FY2019 | $59.2M | +90.6% |
| FY2018 | $31.0M | -26.7% |
| FY2017 | $42.3M | -26.6% |
| FY2016 | $57.7M | +38.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026